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Background: Malignant ovarian disease is characterised by high rates of mortality due to high rates of recurrent
chemoresistant disease. Anecdotal evidence indicates this may be due to chemoresistant properties of cancer stem
cells (CSCs). However, our understanding of the role of CSCs in recurrent ovarian disease remains sparse. In this
study we used gene microarrays and meta-analysis of our previously published microRNA (miRNA) data to assess
the involvement of cancer stemness signatures in recurrent ovarian disease.
Methods: Microarray analysis was used to characterise early regulation events in an embryonal carcinoma (EC)
model of cancer stemness. This was then compared to our previously published microarray data from a study of
primary versus recurrent ovarian disease. In parallel, meta-analysis was used to identify cancer stemness miRNA
signatures in tumor patient samples.
Results: Microarray analysis demonstrated a 90% difference between gene expression events involved in early
regulation of differentiation in murine EC (mEC) and embryonic stem (mES) cells. This contrasts the known parallels
between mEC and mES cells in the undifferentiated and well-differentiated states. Genelist comparisons identified a
cancer stemness signature set of genes in primary versus recurrent data, a subset of which are known p53-p21
regulators. This signature is present in primary and recurrent or in primary alone but essentially never in recurrent
tumors specifically. Meta-analysis of miRNA expression showed a much stronger cancer stemness signature within
tumor samples. This miRNA signature again related to p53-p21 regulation and was expressed prominently in
recurrent tumors. Our data indicate that the regulation of p53-p21 in ovarian cancer involves, at least partially, a
cancer stemness component.
Conclusion: We present a p53-p21 cancer stemness signature model for ovarian cancer. We propose that this may,
at least partially, differentially regulate the p53-p21 mechanism in ovarian disease. Targeting CSCs within ovarian
cancer represents a potential therapeutic avenue.
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Background
Ovarian cancer is the leading gynecological malignancy,
affecting more than 200,000 women per annum world-
wide [1,2]. This is largely due to high rates of chemore-
sistant recurrence associated with the disease. Primary
ovarian cancer develops silently, with most patients symp-
tom-free, only presenting at an advanced stage. Treatment
of primary disease generally consists of surgical removal of
the malignancy in combination with platinum-based treat-
ments. In recent years, chemotherapeutic agent carbopla-
tin has proved successful in eliminating primary
malignancy while reducing side effects for the patient
[Reviewed in [3]]. Mechanistically, platinum-based drugs
bind nucleotides within the DNA backbone, causing
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mechanisms that ultimately result in apoptosis. Today, the
majority of primary ovarian malignancies are successfully
treated, where up to 80% of women will recover [2]. The
remaining 20% may be explained by late presentation of
the disease by asymptomatic women. Alarmingly, up to
80% of these survivors will develop chemoresistant term-
inal recurrent disease within two years, which is accepted
as the main factor in fatality rates. We have previously
used comparative microarray analysis to demonstrate that
primary and recurrent disease have substantially different
gene and microRNA (miRNA) expression profiles [4,5],
which we continue in this study.
Current treatment of recurrent disease, which is simi-
lar to treatment of primary disease, has proved ineffec-
tive. Thus, recurrent disease must be fully characterised
and novel therapeutic approaches developed. One such
approach involves targeting cancer cells with stemness
properties. These cancer stem cells (CSCs) have been
described in ovarian cancer [Reviewed in [6]] and have
several properties with relevance to recurrent ovarian
cancer. CSCs are sufficient to regenerate malignancy in
vivo via extensive self-renewal and differentiation.
Tumor regeneration from CSCs is remarkably efficient,
where a single CSC is often sufficient to re-establish dis-
ease [7,8]. CSCs proliferate well in the hypoxic condi-
tions found in the tumor microenvironment [9,10]. As
they differentiate, CSCs quickly develop neo-vasculature
to fuel further tumorigenesis. Perhaps the most alarming
aspect of CSCs is their uninhibited proliferation in the
presence of chemotherapeutic agents. It is broadly
accepted that CSCs play a role in most, if not all, pri-
mary malignancies. Theoretically, the persistence of a
single CSC post-intervention could be sufficient to
explain chemoresistant recurrence. However, the role of
CSCs in recurrent ovarian disease is poorly understood.
Ultimately we must develop methods of targeting speci-
fic CSC populations as part of a combined anti-cancer
strategy.
Many studies have demonstrated the presence of CSCs
in ovarian malignancy [6]. However, establishing ovarian
CSC models in culture has proved challenging. In this
study we employed an embryonal carcinoma (EC) model
of cancer stemness. Originally derived from malignant
teratomas that can develop in the ovary, EC cells are the
original and best characterised CSC model [11-14]. We
have previously shown high relevance between EC cells
and ovarian serous carcinoma patient samples at the
miRNA level [15]. Pluripotent EC cells can differentiate
into cells representing all three germ layers and are con-
sidered the malignant equivalent of embryonic stem
(ES) cells [11-14]. Nullipotent EC cells can avoid differ-
entiation in vivo to generate poorly-differentiated,
highly-malignant tumors [11-14]. Comparison of ES
cells with pluripotent and nullipotent EC cells can
establish mechanisms required for functional malignant
differentiation. The cells are so similar that EC cells are
used as an easily cultured model of ES biology, reflect-
ing the difficulty of targeting CSCs without damaging
non-malignant stem cell populations [16-18].
In this study we first used gene microarrays to assess
upstream regulation of differentiation in murine EC
(mEC) and mES cells. Our analysis describes aberrant
regulation of differentiation in EC cells. Subsequently,
we compared mEC genelists to our previously published
primary versus recurrent tumor sample data [5]. We
described the presence of a cancer stemness p53-p21
regulatory mechanism in ovarian tumor samples. This
mechanism is employed by primary disease and sup-
pressed in recurrent disease. Subsequently, we con-
ducted a meta-analysis of our previously published
human EC (hEC) and tumor sample miRNA data [15,6].
We report that cancer stemness signature miRNAs are
more relevant to ovarian cancer than cancer stemness
signature genes. We detail substantial recruitment of
stemness signature miRNAs by recurrent disease. Thus
recurrent tumors suppress and activate stemness signa-
ture genes and miRNAs respectively. Our analysis indi-
cates that cancer stemness mechanisms are specifically
and differentially regulated in primary and recurrent




Murine ES (ES-E14TG2a) and EC cells (pluripotent
‘SCC-PSA1’ and nullipotent ‘Nulli-SCC1’)w e r ep u r -
chased from ATCC, cultured on murine irradiated fibro-
blasts in DMEM supplemented with 10% foetal bovine
serum, 4 mM L-glutamine (Invitrogen) and 100 U/ml of
penicillin/streptomycin (Invitrogen Corporation, Carls-
bad, CA, USA) and spontaneously differentiated via
removal of feeder layer. Human EC cells were retinoic
acid-differentiated as previously described [15].
Tumor Samples
Tumor sample data was previously published [5,6].
Briefly, two cohorts of primary and recurrent samples
were assessed. Cohort 1 contained 5 primary and recur-
rent serous papillary adenocarcinomas (Grade 3). Cohort
2 contained 3 paired ovarian cancers from the same
patient but with different histologies: papillary serous,
mixed mullerian and clear cell carcinomas.
Microarray Analysis
RNA was isolated using the RNeasy kit (Qiagen, West
Sussex, UK) as per manufacturer’sp r o t o c o l .D i g o x i -
genin-UTP labelled cRNA was synthesized via the
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Technologies, Foster City, CA, USA) and hybridized to
Mouse Genome Survey arrays (Life Technologies) as per
manufacturers’ instructions. Data was filtered to a sig-
nal/noise ration threshold > 3 in at least one sample
using R and further analysed using Spotfire
® (Life Tech-
nologies). Genelists were generated using cut-offs of
0.05 (p-Value) and ± 2.0 (fold change). Functional rela-
tionships were analysed using DAVID [19,20]. Pathways
associations of predicted targets of miRNAs highlighted
were generated using DIANA miRPath [21] using cut-
offs of ≥ 2 genes per pathway and p-value ≤ 0.05.
qPCR Analysis
2 μg total RNA was used to synthesis cDNA using the
High Capacity cDNA Archive Kit (Life Technologies) as
per manufacturer’s instructions. Microarrays were vali-
dated using 36 pre-designed TaqMan assays (Life Tech-
nologies). Gene expression values were generated using
the 2^-ddCt method [22]. microRNA was isolated using
the mirVANA kit (Ambion) and miRNA TaqMan qPCR
(Life Technologies) [23] analysis carried out as pre-
viously described [5,6,15]. Data plotted represents the
mean value across a minimum of n = 3. Error bars
represent standard error of the mean.
Results
Microarray analysis of early mEC and mES differentiation
It is well established that ES and EC cells express similar
gene profiles in the undifferentiated and well-differen-
tiated (one week or later) states [16,11,17,18]. In con-
trast, our understanding of the earlier, upstream
regulation of differentiation is sparse. We hypothesized
that comparison of early differentiation of mES and
mEC cells would identify cancer-specific differences in
upstream regulation of stem cell differentiation. Addres-
sing this we used microarray analysis to assay early
(three day) differentiation of mES and mEC cells.
Microarray data was validated through qPCR analysis,
showing excellent correlation (Figure 1). An overview of
the number of differentially expressed genes in pluripo-
tent (SCC-PSA1) and nullipotent (Nulli-SCC) mEC and
mES cells is shown in Table 1. At cut-offs of 0.05 (p-
Value) and ± 2.0 (fold change) SCC-PSA1 cells alter the
expression of 724 genes: 202 upregulated and 522 down-
regulated at fold change levels between +18 and -18
(Additional File 1). Top ten SCC-PSA1 genes are char-
acterised by receptor activity and growth and differentia-
tion/development roles (Table 2). Noteworthy events
include upregulation of apoptosis (Bcl)-related gene
Bid3 and downregulation of Cav2 tumor suppressor [24]
and metastasis-linked Nupr1 [25]. Functional relation-
ship analysis identified upregulation of developmental
pathways and downregulation of transcription regulation
processes and Toll-Like Receptor (TLR), Interleukin-2
and cancer pathways (Additional File 1).
Nulli-SCC cells responded to differentiation stimuli
through the upregulation of 185 and downregulation of
152 genes at levels from -6.3 to 14.0 fold (Additional
File 2). Top ten genes included signal transducers and
regulators of development/differentiation and malig-
n a n c y( T a b l e2 ) .N o t a b l eg e n e si n c l u d eh y p o x i aa n d
tumor growth regulator Loxl2 [26] and tumor suppres-
sor Serpini2 [27]. Interestingly Ssa2 is downregulated, a
gene that is commonly expressed on the surface of
apoptotic cells. Functional analysis identified upregula-
tion of signal transduction regulators and downregula-
tion of growth regulators (Additional File 2).
Upstream differentiation of mES cells is characterized
by substantial levels of upregulation: 554 upregulated
and 832 downregulated genes at levels of 232 to -68
fold (Additional File 3). Top ten genes are populated
with receptors and developmental regulators (Table 2).
Tll1 is linked to cardiac development, the first organised
system formed during embryogenesis. Notably, a key
RNAi gene, Eif2c4, is upregulated during differentiation,
Figure 1 Validation of mEC and mES microarray data. Microarray data was validated through qPCR (TaqMan) analysis of a group of 36
genes. Data presented represents gene expression change in differentiated cells compared to undifferentiated and shows good correlation for
mES (A) and PSA-SCC1 (B) datasets.
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[28]. Upregulated mES genes regulate development, sig-
nalling and gene expression while downregulated genes
regulate morphogenesis, particularly growth factor bind-
ing. Stemness-linked pathways such as Wnt-catenin and
Hedgehog signalling were upregulated while signalling
pathways including TLR and TGF-ß were downregu-
lated (Additional File 3).
Aberrant upstream regulation of differentiation in mEC
cells
A comparison of mES and mEC early differentiation
genelists is summarised in Table 1 and detailed in addi-
tional files 1, 2 and 3. In contrast to documented undif-
ferentiated and well-differentiated comparisons, 90% of
the mES genelist differed to the mEC genelist at this
Table 1 An overview of the numbers and percentage
overlap of differentially expressed genes (D/U) during
early differentiation of mES and mEC cells.
Cell Type Gene Number % Overlap
Upreg Downreg mES SCC-PSA1 Nulli-SCC
mES 554 832 10 < 1
SCC-PSA1 202 522 33 < 1
Nulli-SCC 185 152 < 1 < 1
Table 2 Top ten genes differentially expressed (D/U)
during early differentiation of mES and mEC cells.




Olfr1450 Olfactory receptor 1450 9.0
Fgf5 Fibroblast growth factor 5 8.9
Dscam Down syndrome cell adhesion molecule 7.7
Afp Alpha fetoprotein 5.2
Rbp4 Retinol binding protein 4, plasma 5.0
Slc28a2 Solute carrier family 28, member 2 4.5
Bid3 BH3 interacting domain, apoptosis
agonist
4.3
Igfbp5 Insulin-like growth factor binding protein
5
4.2
Irs4 Insulin receptor substrate 4 3.8
Downregulated
Clec2d C-type lectin domain family 2, member d -11.3
Fbln5 Fibulin 5 -6.5
Cav2 Caveolin 2 -5.6
Irf5 Interferon regulatory factor 5 -5.5
Lsp1 Lymphocyte specific 1 -5.1
Olfr787 Olfactory receptor 787 -4.9
Fxyd4 FXYD-containing ion transport regulator
4
-4.8
Nupr1 Nuclear protein 1 -4.7
Table 2 Top ten genes differentially expressed (D/U) dur-
ing early differentiation of mES and mEC cells.
(Continued)
Kcnk4 K channel, subfamily K, member 4 -4.6
Cpne2 Copine II -4.6
Nulli-SCC
Upregulated
Flt1 FMS-like tyrosine kinase 1 5.3
Npy5r Neuropeptide Y receptor Y5 5.0
Olfr786 Olfactory receptor 786 4.4
Fau FBR-MuSV ubiquitously expressed 4.1
Gm392 Gene model 392, (NCBI) 3.7
Gm449 Gene model 449, (NCBI) 3.2
Loxl2 Lysyl oxidase-like 2 2.9
Aoc3 Amine oxidase, copper containing 3 2.8
Serpini2 Serine proteinase inhibitor 1 2.8
Olfr870 Olfactory receptor 870 2.7
Downregulated
Ssa2 Sjogren syndrome antigen A2 -5.3
4930486G11Rik RIKEN cDNA 4930486G11 gene -4.6
1700052K11Rik RIKEN cDNA 1700052K11 gene -4.5
Refbp2 RNA and export factor binding protein 2 -4.4
2900011O08Rik RIKEN cDNA 2900011O08 gene -3.7
Tmem62 Transmembrane protein 62 -3.7
Tirap TIR domain-containing adaptor protein -3.6
Defb13 Defensin beta 13 -3.5
Es31 Esterase 31 -3.4
Nap1l5 Nucleosome assembly protein 1-like 5 -3.3
mES
Upregulated
H1foo H1 histone family, member O, oocyte-
specific
64.2
Mrgprh MAS-related GPR, member H 60.8
Mak10 MAK10 homolog 59.6
V1rd11 Vomeronasal 1 receptor, D11 57.8
B230317F23Rik RIKEN cDNA B230317F23 gene 41.1
Gdpd3 Glycerophosphodi- phosphodiesterase 3 39.2
Na Gene model 979, (NCBI) 32.3
Eif2c4 Euk translation initiation factor 2C, 4 30.6
Tll1 Tolloid-like 22.9
Na Similar to Ig gamma-2a chain precursor 20.1
Downregulated
MP4 Proline rich protein MP4 -70
Pck1 Phosphoenolpyruvate carboxykinase 1 -49.3
Fgfrl1 Fibroblast growth factor receptor-like 1 -38.3
Rpgrip1l Rpgrip1-like -20.6
Olfr508 Olfactory receptor 508 -16.0
Eif5a2 Euk translation initiation factor 5A2 -15.6
9130015A21Rik RIKEN cDNA 9130015A21 gene -14.6
Tecta Tectorin alpha -11.0
Fancc Fanconi anemia, complementation group
C
-10.7
Pax9 Paired box gene 9 -9.9
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SCC-PSA1 genelist differed from the mES genelist
(Table 1). Functional relationship analysis indicates that
quite different mechanisms are activated during early
differentiation of mEC and mES cells. This included
mES-specific upregulation of p53 signaling pathway
genes (Additional File 3). There is very little overlap
between Nulli-SCC and the other cell types (Additional
Files 1, 2 and 3). Only four genes are upregulated by
SCC-PSA1 and downregulated by Nulli-SCC cells, while
only two are downregulated by both cell types. The
downregulation of symporters, signal-transducing mem-
brane proteins, which are upregulated by pluripotent
cells, may indicate a potential counteraction of differen-
tiation. Upstream regulation of differentiation represents
a substantial difference between these cell types, sup-
porting our hypothesis. While similar genes maintain
the self-renewal state in each cell, different mechanisms
are employed to regulate the early events in
differentiation.
A SCC-PSA1 p53 mechanism is expressed in primary and
maintained in recurrent tumors
We have previously published microarray analysis of pri-
mary versus recurrent tumor samples [5,6]. The study
contained two cohorts. Cohort 1 represents a group of
matched primary and recurrent tumors while cohort 2
represents primary and recurrent tumor samples from
the same patients. In this study, raw microarray data
from the primary versus recurrent study was reanalysed
in an identical fashion to mES and mEC data described
above (Additional File 4). Primary versus recurrent dis-
ease and mEC genelists were then compared. Genes
altered similarly in mEC and mES data were not consid-
ered to be cancer-specific and were removed from this
analysis. Comparison of mEC and tumor data identified
16 SCC-PSA1 genes expressed in tumor samples
(Figure 2, Table 3). These genes group into those that
are A) expressed in both primary and recurrent tumors
and B) those expressed in primary but not recurrent
tumors (Table 3). Many of these genes have links to
stemness and malignancy. Tmprss2 is a transmembrane
signalling protein that is upregulated in prostate cancer
[29]. Cthrc1 is a Smad2/3 (TGF-b signalling) inhibiting
Wnt signalling modulator that is differentially expressed
in invasive breast cancer and several solid tumors [30].
Nkx3-1 is a metastatic marker transcription factor
expressed in prostate cancer [31]. Pdgfc is a cisplatin-
associated growth factor [32]. Col4a5 is linked to several
cancers while Plaur is a regulator of tissue reorganisa-
tion [33]. Ndufs6 is an oxidative phosphorylation
Figure 2 Expression of SCC-PSA1 stemness signature mRNAs in recurrent tumors. Sixteen genes were identified as differentially expressed
in SCC-PSA1 mEC cells and in tumor data. Data is presented as the percentage change in gene expression in differentiated compared to
undifferentiated SCC-PSA1 cells (blue) and in primary tumor samples compared to recurrent (red). Gene Expression values are detailed in table 3
(Microarray data p-Value ≤ 0.05).
Table 3 Percentage gene expression of mEC-specific
genes expressed in primary versus recurrent tumor
samples (Group A expressed similarly in primary and
recurrent samples).
% Gene Expression % Gene Expression
Gene Name Tumor SCC-PSA1 Gene Name Tumor Nulli-SCC
(P/R) (U/D) (P/R) (U/D)
Group A Group A
Dusp26 325.2 Egln3 259.9
Hsf2 222.5 Ndufab1 245.4
Pdzk1 212.8 Gpr6 229.6
Sdsl 226.2 Ltbr 212.2
Ndufs6 -203.1 Golga5 -208.5
Sox4 -208.1 Slc15a1 -214.6
Group B Gpatc3 -236.7
Itgbl1 432.6 -396.1 Dgcr8 -323.3
Kcnmb4 397.0 267.5 Tirap -364.3
Nkx3-1 375.2 260.0 Group B
Tmprss2 368.3 373.0 Cask 442.1 -220.5
Cthrc1 334.6 298.7 Stau2 292.9 -201.6
Pdgfc 283.2 -392.8 Bnip3 283.4 217.4
Plaur 259.9 -263.2 Pfkp 239.4 251.0
Hoxb2 239.3 -375.5 Pak6 202.4 -213.8
Col4a5 210.8 -320.7
Gata2 -276.5 -243.0
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oestrogen-sensitivity in breast and ovarian cancers [35].
Sdsl is a cancer-specific metabolic enzyme [36]. Only
one gene, Gata2, an endodermal differentiation marker
[37] was upregulated by mEC cells and expressed higher
in primary tumors than in recurrent.
When scrutinised, we noted that several of the genes
highlighted above have been defined as p53 regulators
in various models, as now described. Dusp26 is a p53-
inhibiting phosphatase that negatively regulates prolif-
eration of epithelial cells [38]. Stemness gene Sox4 is a
p16 and p53 regulator in cancer cells [39] while Hsf2 is
a regulator of p53 stability [40]. Hoxb2 has been linked
to p205 regulation of p53 and is a well known regulator
of EC differentiation [41]. Collectively, our analysis indi-
cates that both primary and recurrent ovarian tumors
express this ‘p53-regulating stemness signature’.
A NULLI-SCC p21 mechanism is suppressed by recurrent
tumors
Despite the reduced genelist size, 14 Nulli-SCC genes were
expressed in A) both primary and recurrent tumors or B)
p r i m a r yt u m o r so n l y( F i g u r e3 ,T a b l e3 ) .T h e s eg e n e s
related to apoptosis/cellular proliferation, signaling and
regulation. Dgcr8 (Pasha) is a key miRNA biosynthesis
gene [42], while Tirap is a regulator of TLR signaling [43].
TNF-family related Ltbr and hypoxia-linked Egln3 are
apoptosis regulators [44,45]. Gpr6 is a development regu-
lator expressed in umbilical cord cells [46]. Ndufab1 is a
TGF-b signaling related NADPH enzyme [47]. Slc15a1 is
involved in drug absorption in the small intestine and has
been linked to several cancers and metastasis [48].
Coupled with this is the recurrent suppression of apopto-
sis regulators Bnip3 and Stau2 [49,50]. Notably, two p21
regulators are expressed higher in primary tumors com-
pared to recurrent: Cask mediates the expression of p21 to
control cell proliferation [51] while Pak6 is a p21
interacting kinase that is a required for chemoresistance in
prostate cells [52]. Collectively, an EC cancer stemness sig-
nature expressed in tumor samples is linked to maintained
p53 regulation and suppression of p53’s main target, p21,
in recurrent disease.
Recruitment of cancer stemness signature miRNAs during
recurrence
Having identified gene level overlaps, we next conducted
overlap meta-analysis of our previously published miRNA
data for primary and recurrent patient samples and
human EC (hEC) early (three day) differentiation [5,6,15].
The earlier study identified cancer stemness signature
miRNAs: those miRNAs involved in the differentiation of
hEC cells. Specifically, our previous tumor study high-
lighted 60 miRNAs (52 up and 8 downregulated) in recur-
rent disease [6]. Of these, 55 miRNAs (92%) are expressed
in hEC cells (Additional File 5). 21 recurrent disease-speci-
fic miRNAs are linked to differentiation of pluripotent
NTera2 hEC cells (Figure 4). We have previously shown
that nullipotent 2102Ep hEC cells express a large number
of miRNAs at substantially higher levels than NTera2 cells
[15]. Here we report that 26 (43%) recurrent disease-speci-
fic miRNAs are expressed at higher levels in 2102Ep cells
than in NTera2 (Figure 5). Thus, development of recurrent
tumors involves recruitment of cancer stemness signature
miRNAs. Specific examples include miR-9, which is the
most downregulated miRNA in recurrent tumors and is >
1000% higher expressed in undifferentiated 2102Ep cells
compared to NTera2, and miR-206, which is in the top
ten miRNAs upregulated by recurrent tumors and down-
regulated during NTera2 differentiation. Molecular path-
way relationships between predicted gene targets of the
miRNAs highlighted were identified using DIANAmir-
PATH (Additional file 5). While little pathway overlap was
observed in gene array data, miRNA data showed strong
pathway associations. Pathway analysis highlighted
Figure 3 Expression of Nulli-SCC stemness signature mRNAs in recurrent tumors. Fourteen genes were identified as differentially expressed
in Nulli-SCC mEC cells and in tumor data. Data is presented as the percentage change in gene expression in differentiation-stimulated compared
to undifferentiated Nulli-SCC cells (blue) and in primary tumor samples compared to recurrent (red). Gene Expression values are detailed in table
3 (Microarray data p-Value ≤ 0.05).
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expressed in differentiated NTera2 hEC cells and in tumor data. Data is presented as the percentage change in miRNA expression in
differentiated NTera2 hEC cells (blue) and in recurrent tumors compared to primary (red). Values represent the mean of at least n = 3 and error
bars the standard error of the mean.
Figure 5 Expression of 2102Ep stemness signature miRNAs in recurrent tumors. Twenty six miRNAs were identified as differentially
expressed in undifferentiated 2102Ep compared to undifferentiated NTera2 hEC cells and in tumor data. Data is presented as log10 (fold
change). miRNAs presented showed altered expression in undifferentiated 2102Ep cells compared to undifferentiated NTera2 (blue) and in
recurrent tumors compared to primary (red). Values represent the mean of at least n = 3 and error bars the standard error of the mean.
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-106, -107, -128 and let-7g) as well as Wnt and TGF-b
stemness signaling pathways (mirs-10b, -100, -106, -128a
and 137). Finally, we assessed the expression of p53-p21
regulating miRNAs in these datasets. Two miRNAs, miRs-
106a and b, are validated targets of p21 [52] that are upre-
gulated in recurrent disease and expressed in hEC cells.
Notably, miR-106b expression in 2102Ep cells is double
that of NTera2 cells. In contrast, miR-155, the only vali-
dated p53-regulating miRNA, is unaltered in recurrent
tumors. We note that the p53 signaling pathway was high-
lighted for let-7g and miRs-106b and -107 in pathway ana-
lysis (Additional file 5). In overview, we find that miRNAs
linked to 2102Ep malignancy are highly relevant to pri-
mary and recurrent tumors.
Discussion
Although CSCs are obvious suspects in the development
of recurrent ovarian malignancy, a relationship has yet to
be established or described in detail. Anecdotal evidence
includes altered regulation of Notch3 in chemoresistant
ovarian disease and the clear parallel between epithelial-
mesenchymal transition (EMT) and CSC differentiation
mechanisms [53,54]. In this study we conducted microar-
ray and meta-analysis of mRNA and miRNA expression
in primary and recurrent tumor samples and an EC
model of cancer stemness. Our analysis reiterates that
development of primary and recurrent ovarian disease
involves quite different mechanisms: thousands of genes
are differentially expressed. At the gene level, recurrent
tumors appear to repress a cancer stemness signature
related to p53-p21 regulation. In parallel, recurrent
tumors recruit a population of miRNAs with close links
to the development of highly malignant, poorly-differen-
tiated tumors from nullipotent hEC cells.
Different genetic profiles are employed by primary and
recurrent ovarian tumors [5,6]. In this study we demon-
strate that malignant stem cell differentiation genes are
expressed in either primary tumors or both primary and
recurrent tumors but essentially never in recurrent
tumors-specifically. Some CSC mechanisms are similarly
employed in primary and recurrent tumorigenesis. In
addition, an obvious implication of our study is that
CSCs that survive chemotherapy to repopulate recurrent
disease can do so using different mechanisms than those
employed in primary disease. Functional relationship
analysis indicated that these stemness signature genes
have a particular relevance to cellular proliferation and
apoptosis. Several of the genes highlighted are known
‘p53-p21 signaling regulators’. Mechanistically this
relates to regulation of p53-p21 processes, where p53
regulation is enhanced and p21 regulation no longer
required in recurrent tumors. This is supported by
increased expression of p21 repressing miRNAs in
recurrent tumors and strong predicted targeting of p53
signaling genes by tumor-specific miRNAs. Altered p53-
p21 regulation is the primary mechanism through which
cancers avoid apoptosis and stimulate cellular prolifera-
tion. Predictably, we did not find loss of p53 or p21 in
recurrent disease (data not shown). It appears that p53-
p21 regulation is required at both stages of ovarian
malignancy. In Figure 6 we present a schematic to
Figure 6 Suppression of cancer stemness p53-p21 regulation in recurrent tumors. Primary disease is characterised by the expression of
p53-regulating stemness signature genes Sox4 and Sdsl, which is continued and enhanced with Dusp26 expression in the recurrency. In
contrast, p21 regulating stemness signature genes Pak6 and Cask are expressed in primary disease and suppressed in recurrency. This process is
paralleled by recruitment of stemness signature miRNAs by recurrent disease.
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study. We propose that these genes and miRNAs regu-
late p53-p21 signaling, at least partially, in primary and
recurrent disease (Figure 6). Indeed, this is likely to be a
component of a larger mechanism. This p53-p21 regu-
lating component appears to play a role in primary
tumors that is not used during recurrence. We refer to
this as a p53-p21 regulating mechanism within the can-
cer stemness signature (genes altered during differentia-
tion of EC cells but not by ES cells). As a key
tumorigenesis component, differential regulation of
stemness-linked p53-p21 mechanisms in primary and
recurrent disease is an important outcome of this study
and will be the subject of ongoing analysis.
It is well established that EC and ES cells are highly
similar in the undifferentiated and well-differentiated
states [16-18]. This illustrates the significant challenges
to the concept of targeting CSCs in a manner that
does not harm the non-malignant stem cell pool. In
this study we have identified upstream regulation of
differentiation as a substantial difference between EC
and ES cells, supporting our hypothesis. While down-
regulated mEC and mES genes displayed similarity,
upregulated SCC-PSA1 genes were almost 90% specific
to malignancy. This supports a model where normal
and malignant stem cells employ similar mechanisms
to maintain the self-renewal state. The different phe-
notypes developing from differentiation, therefore, are
related to activation of specific malignant or non-
malignant genes. Both cell types alter genes related to
similar processes: receptor-mediated signalling of
development/differentiation. Thus the differentiation of
malignant and non-malignant cells is driven by a diver-
gent group of genes. It is noteworthy that the primary-
recurrent genetic switch contained an equally strong
Nulli-SCC cell signature, despite the much reduced
genelist. Nulli-SCC cells avoid differentiation through
maintained levels of gene and miRNA expression to
generate highly malignant tumors [11]. While a small
number of molecular events take place in these cells
response to differentiation, these appear to have a par-
ticular relevance to the difference between primary and
recurrent disease. Stemness genes are never expressed
by recurrent disease only, suggesting a less stem-like
profile. These genes have a particular relevance to cel-
lular proliferation and apoptosis, including p53-p21
regulation. Of particular note is the downregulation in
Nulli-SCC cells of TLR signaling adapter Tirap, a gene
that is constantly expressed in primary and recurrent
disease. TLR signaling has received increased attention
in both cancer and stemness studies in recent years
[55]. In summary, recurrent disease appears to have
more correlation with nullipotent cells rather than EC
cells with good differential potential.
Recurrent tumor development involves the suppression
of twice as many genes as are specifically activated
(Cohort 1). This indicates that recurrent malignancy does
not require a substantial number of mechanisms
employed by primary tumors. Specifically, angiogenesis
and development genes are turned off by recurrent dis-
ease as malignancy genes are turned on. The upregula-
tion of polycystic ovary-associated gene Fabp4 and
ovarian cancer gene Prkcbp1 may be of particular impor-
tance. There was little overlap between genes altered in
cohort 1 and cohort 2, which altered genes more asso-
ciated with malignancy and less with differentiation.
Functional relationship analysis revealed that recurrent
disease no longer requires homeostasis or stimulus
response processes while upregulating catalytic activity
and protein binding process. In general, recurrent disease
behaves more as a developing cancer rather than the che-
mical stress responses required by primary disease.
Conclusion
CSCs targeting is a potential avenue through which treat-
ment of recurrent, chemoresistant ovarian cancer may be
improved. This is complicated by the similarities between
cancer and non-cancer stem cells and our poor under-
standing of recurrent ovarian disease. We have identified
the early events of stem cell differentiation as a key area
of difference between cancer and non-cancer stem cells.
Furthermore, we have highlighted the association of a
p53-p21 related cancer stemness signature within ovarian
disease. Our data suggests that a stem cell involved in
development of recurrent disease employs different
mechanisms of tumorigenesis. Our study suggests that it
may be possible to target early differentiation events in
CSCs without damaging non-cancer stem cells, which
would have broad implications for treatments. Our data
indicates that such therapies should be independently tai-
lored for primary and recurrent ovarian disease. CSC tar-
geting during treatment of primary disease is likely to
have a negative impact on recurrent tumorigenesis. CSC
targeting in recurrent disease should be developed with
consideration to independent mechanisms. Development
of strategies to achieve this will continue in our group.
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Additional file 1: Microarray and functional relationship analysis of
early differentiation response of SCC-PSA1 cells.Microarray and
functional relationship analysis of early differentiation response of
SCC-PSA1 cells. This file contains genelists of genes upregulated and
downregulated by SCC-PSA1 cells in response to differentiation stimulus.
This file also contains results of analysis to identify functional
relationships between these genes.
Additional file 2: Microarray and functional relationship analysis of
early differentiation response of NULLI-SCC cells.Microarray and
functional relationship analysis of early differentiation response of
NULLI-SCC cells. This file contains genelists of genes upregulated and
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Page 9 of 11downregulated by NULLI-SCC cells in response to differentiation stimulus.
This file also contains results of analysis to identify functional
relationships between these genes.
Additional file 3: Microarray and functional relationship analysis of
early differentiation response of mES cells.Microarray and
functional relationship analysis of early differentiation response of
mES cells. This file contains genelists of genes upregulated and
downregulated by mES cells in response to differentiation stimulus. This
file also contains results of analysis to identify functional relationships
between these genes.
Additional file 4: Microarray and functional relationship analysis of
primary versus recurrent tumor samples.Microarray and functional
relationship analysis of primary versus recurrent tumor samples.
This file contains genelists of genes upregulated and downregulated in
primary versus recurrent tumor samples. This file also contains results of
analysis to identify functional relationships between these genes.
Additional file 5: Comparison of microRNA expression in hEC and
primary versus recurrent tumor samples.Comparison of microRNA
expression in hEC and primary versus recurrent tumor samples. This
file details the relative expression patterns and levels of microRNAs in
hEC cells and primary versus recurrent tumor samples and the pathway
associations of genes targeted by these microRNAs.
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